ReviewPharmacology research & perspectives2026
The Bile Acid Signaling Axis: Deciphering the Roles of FXR and TGR5 in Hepatic Steatosis, Fibrosis, and Cancer.
Review in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Bile acids (BAs) serve not only as emulsifiers for lipid digestion but also as essential signaling molecules, governing various physiological and pathological processes through their interaction with the farnesoid X receptor (FXR) and the takeda G protein-coupled receptor 5 (TGR5). In recent years, the critical roles of FXR and TGR5 in ameliorating hepatic steatosis, modulating inflammatory responses, and regulating glucose and lipid metabolism, as well as in cholestasis, have gained significant recognition, positioning them as pivotal targets in liver disease research. This article offers a comprehensive review of the structural characteristics and physiological functions of both FXR and TGR5, highlighting their integral contributions to the pathogenesis and progression of various liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), cholestatic liver disease (CLD), liver fibrosis, and liver cancer. Additionally, it examines the latest advancements in the research and development of pharmacological agents targeting FXR and TGR5, encompassing both agonists and antagonists, and explores their potential clinical applications. A thorough understanding of the FXR and TGR5 signaling pathways will provide a critical theoretical foundation for the development of treatment strategies for liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.